Utility of gonadotropin-releasing hormone agonists for fertility preservation in young breast cancer patients: the benefit remains uncertain (Q38109554)

From Wikidata

Jump to navigation Jump to search

scientific article published on 24 May 2013

Language	Label	Description	Also known as
English	Utility of gonadotropin-releasing hormone agonists for fertility preservation in young breast cancer patients: the benefit remains uncertain	scientific article published on 24 May 2013

Statements

scholarly article

1 reference

Europe PubMed Central

29 August 2017

Utility of gonadotropin-releasing hormone agonists for fertility preservation in young breast cancer patients: the benefit remains uncertain (English)

1 reference

Europe PubMed Central

29 August 2017

1 reference

based on heuristic

inferred from title

author name string

N H Turner

1

1 reference

Europe PubMed Central

29 August 2017

A Partridge

2

1 reference

Europe PubMed Central

29 August 2017

G Sanna

3

1 reference

Europe PubMed Central

29 August 2017

A Di Leo

4

1 reference

Europe PubMed Central

29 August 2017

L Biganzoli

5

1 reference

Europe PubMed Central

29 August 2017

publication date

24 May 2013

1 reference

Europe PubMed Central

29 August 2017

Annals of Oncology

1 reference

Europe PubMed Central

29 August 2017

24

1 reference

Europe PubMed Central

29 August 2017

9

1 reference

Europe PubMed Central

29 August 2017

2224-2235

1 reference

Europe PubMed Central

29 August 2017

Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Occurrence of breast cancer subtypes in adolescent and young adult women

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes?

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Web-based survey of fertility issues in young women with breast cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Premature ovarian failure and its consequences: vasomotor symptoms, sexuality, and fertility

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Fertility (male and female) and menopause

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

The variability of female reproductive ageing

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Predictors of ovarian reserve in young women with breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Very young women (<35 years) with operable breast cancer: features of disease at presentation.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Fertility- and menopause-related information needs of younger women with a diagnosis of early breast cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Preservation of fertility and ovarian function and minimalization of chemotherapy associated gonadotoxicity and premature ovarian failure: the role of inhibin-A and -B as markers

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Fertility preservation and pregnancy in women with and without BRCA mutation-positive breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Adjuvant docetaxel for node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Efficiency of oocyte cryopreservation: a meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Delivery rate using cryopreserved oocytes is comparable to conventional in vitro fertilization using fresh oocytes: potential fertility preservation for female cancer patients

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Vitrification of oocytes produces high pregnancy rates when carried out in fertile women

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Aromatase inhibition reduces the dose of gonadotropin required for controlled ovarian hyperstimulation

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Fertility preservation in young women undergoing breast cancer therapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Premature menopause in patients with BRCA1 gene mutation

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing hormone analogue treatment in protecting against chemotherapy-induced gonadal injury

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Protective effects of D-Trp6-luteinising hormone-releasing hormone microcapsules against cyclophosphamide-induced gonadotoxicity in female rats

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Goserelin with chemotherapy to preserve ovarian function in pre-menopausal women with early breast cancer: menstruation and pregnancy outcomes.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Protective effect of leuprolide on ovarian function in young women treated with adjuvant chemotherapy for early breast cancer: a multicenter phase II study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Anti-mullerian hormone predicts menopause: a long-term follow-up study in normoovulatory women

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Anti-Müllerian hormone: a new marker for ovarian function

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Serum anti-Müllerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

High reproducibility of serum anti-Mullerian hormone measurements suggests a multi-staged follicular secretion and strengthens its role in the assessment of ovarian follicular status.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Serum anti-Mullerian hormone throughout the human menstrual cycle.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Value of early referral to fertility preservation in young women with breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT196

21 January 2018

Identifiers

10.1093/ANNONC/MDT196

1 reference

Europe PubMed Central

29 August 2017

1 reference

Europe PubMed Central

29 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38109554&oldid=2115851458"